Q2 FY27 investor presentation: revenue up 28% to ₹ 752 Crore, PAT up 26%
Epigral has shared its investor presentation on the unaudited results for the September 2026 quarter (Q2 FY27).
By ScoutQuest · · 2 min read
- Revenue
- ₹ 752 Crore, up 28% YoY; sales volume grew 6%
- PAT
- ₹ 64 Crore, up 26%
- EBITDA
- ₹ 136 Crore, up 3%; margin at 18%
What this update is
Epigral has enclosed its investor presentation on the unaudited financial results for the quarter ended September 2026, referred to as Q2 FY27. Such a presentation summarises the company's performance and is shared with the exchanges for information and records.
Q2 FY27 in numbers
- Revenue grew by 28% to ₹ 752 Crore, which the company attributes to volume growth and mainly to improved realisations.
- Sales volume grew 6% year on year, which the company describes as achieved despite challenging and volatile market conditions.
- EBITDA grew by 3% to ₹ 136 Crore from ₹ 132 Crore. The company said EBITDA margin was muted on account of high cost of raw materials and stood at 18%.
- PAT grew by 26% to ₹ 64 Crore from ₹ 51 Crore.
- The Derivatives & Specialty business contributed 57% of revenue, compared with 50% in Q2FY26.
First half FY27
- Revenue rose 21% to ₹1,461 Crore from ₹1,204 Crore, which the company notes came even after geopolitical tensions, volatile price movements and an off season for a few of its products.
- EBITDA grew 7% to ₹ 315 Crore from ₹ 296 Crore, with EBITDA margin maintained at 22%.
- PAT rose 25% to ₹ 164 Crore from ₹ 131 Crore; PAT margin stood at 11%.
- Net Debt/EBITDA stood at 0.9x as on 30th September 2026, compared with 0.8x as on 30th September 2025.
How a reader can look at it
- Revenue growth of 28% alongside volume growth of 6% suggests a large part of the increase came from better realisations, that is, higher prices for what was sold, rather than from selling much more.
- Operating profit at the EBITDA level grew far slower than revenue because raw material costs were high; the company itself describes the quarterly EBITDA margin as muted.
- The higher share of the Derivatives & Specialty business in revenue points to a change in the revenue mix between the two periods.
- Net Debt/EBITDA at 0.9x is slightly higher than the 0.8x of a year earlier on this measure.
Points to keep in mind
- The results referred to are unaudited.
- The presentation carries forward-looking statements about future growth prospects, which the company says involve risks and uncertainties that could make actual results differ materially.
Also from Epigral
Epigral Ltd press release, Q2 FY27
2 Nov 2026
Board approves unaudited Q2 and H1 FY27 results; limited review finds no material misstatement
2 Nov 2026
CRISIL AA/Stable and CRISIL A1+ assigned as revised ratings on Rs. 1050 Crore bank facilities
29 Oct 2026
More numbers
- Q2 FY27 revenue₹ 752 Crore
- Q2 FY27 revenue growth28%
- Q2 FY27 EBITDA₹ 136 Crore
- Q2 FY27 PAT₹ 64 Crore
- Q2 FY27 EBITDA margin18%
- H1 FY27 revenue₹1,461 Crore
- H1 FY27 PAT₹ 164 Crore
- Net Debt/EBITDA as on 30th September 20260.9x
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.